
Stereotaxis Inc (STXS) Stock Forecast & Price Target
Stereotaxis Inc (STXS) Analyst Ratings
Bulls say
Stereotaxis Inc. is projected to see substantial revenue growth driven by an increase in system sales adoption and a rise in catheter utilization, with anticipated revenue streams for FY26E reaching $43 million, $12 million, and $31 million, reflecting growth rates of 24%, 20%, and 25%, respectively. The company reported a remarkable 95% year-over-year revenue increase to $8.8 million in the second quarter, alongside strong recurring revenue growth of 35% year-over-year to $5.8 million, bolstered by the successful introduction of the Map-iT and MAGiC ablation catheters. Significant regulatory achievements and the anticipated launch of the GenesisX system are expected to enhance the company’s product portfolio, leading to increased utilization and recurring revenues, which support a favorable outlook for the firm's financial performance.
Bears say
Stereotaxis Inc. is facing several significant challenges that negatively impact its financial outlook, including operating expenses of $8.6 million and a net loss of $3.8 million, highlighting ongoing financial strain. The company is hindered by delays in new product approvals, supply issues with current catheters, reimbursement changes, and growing competition from manual approaches and other robotic platforms, all of which may adversely affect revenue generation. Furthermore, with only two years of cash runway left, Stereotaxis may need to seek additional financing, raising concerns about its long-term sustainability and potential for profitability.
This aggregate rating is based on analysts' research of Stereotaxis Inc and is not a guaranteed prediction by Public.com or investment advice.
Stereotaxis Inc (STXS) Analyst Forecast & Price Prediction
Start investing in Stereotaxis Inc (STXS)
Order type
Buy in
Order amount
Est. shares
0 shares